Company targets new approach to treating rheumatoid arthritis and systemic sclerosis

Early data show faster viral clearance and favourable safety in mild to moderate COVID‑19

New authorisation extends treatment to children with ISS, SGA and Noonan syndrome

Phase 2 study reports significantly accelerated debridement and wound repair in venous leg ulcers

New phase 3 results highlight potential alternative for adults switching from complex regimens

More than 200 participants enrolled as company targets topline data by end of 2026

Oral therapy authorised for ER‑positive, HER2‑negative metastatic disease with ESR1 mutations

Erythromelalgia treatment gains regulatory support following EMA decision

PASO DOBLE sub‑analysis indicates metabolic differences between 2‑drug and 3‑drug HIV regimens

QUASAR long‑term extension results highlight durable clinical and endoscopic outcomes